Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: An indicator of drug resistance

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 9, 2012, Pages 2177-2182

  Blackman, A ^a   May, S ^a   Devasia, R A ^a   Maruri, F ^a   Stratton, C ^a,a   Sterling, T R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SCREENING;

EID: 84866403167     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1552-7     Document Type: Article

References (8)

1. NCCLS. The National Committee for Clinical Laboratory Standards (2003) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved Standard. NCCLS Document; M24-A
2. Madison B, Robinson-Dunn B, George I et al (2002) Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 40(11):3976-3979
3. Devasia RA, Blackman A, Gebretsadik T et al (2009) Fluoroquinolone resistance in M. tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 180 (4):365-370
4. Devasia RA, Blackman A, May C et al (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone crossresistance. J Antimicrob Chemother 63(6):1173-1178
5. Takiff HE, Salazar L, Guerrero C et al (1994) Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38(4):773-780
6. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM (2006) Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50(1):104-112
7. Byrd TF, Green GM, Fowlston SE, Lyons CR (1998) Differential growth characteristics and streptomycin susceptibility of virulent and avirulent Mycobacterium tuberculosis strains in a novel fibroblast-mycobacterium microcolony assay. Infect Immun 66 (11):5132-5139
8. World Health Organization (2008) Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008 392. Geneva